🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesGLP-1 and arterial inflammation — March 2026 Page 4

GLP-1 and arterial inflammation — March 2026

laura_annarbor Sat, Sep 20, 2025 at 3:06 AM 28 replies 1,163 viewsPage 4 of 6
Dr.LipidDallas
VIP Member
2,678
14,567
Dec 2023
Dallas, TX
Sep 20, 2025 at 8:46 AM#16

Just wanted to say — for anyone reading this GLP-1 and arterial thread who is feeling discouraged: it gets better. The first few weeks are the hardest. Hang in there. 💪

8 18pam_stl, wei_SG, cory_ATX and 5 others
Reply Quote Save Share Report
cory_ATX
Member
456
2,123
Jul 2024
Austin, TX
Sep 20, 2025 at 9:03 AM#17

laura_annarbor's experience with GLP-1 and arterial resonates deeply with mine. I went through almost the identical process — starting dose, titration timeline, side effects, everything.

The main difference: I titrated faster. But the overall trajectory has been remarkably similar. Down 48 lbs in 13 months.

One thing I would add that laura_annarbor did not mention: the relationship with food fundamentally changed.

Last edited: Sep 20, 2025 at 11:03 AM
38 14andrew_nyc, Dr.EndoEP, GraceAZ_72 and 35 others
Reply Quote Save Share Report
nick_SD_fit
Member
278
1,234
Sep 2024
San Diego, CA
Sep 20, 2025 at 9:20 AM#18

Saving this for reference. Quality thread.

39 23EndoResFellow, PharmacoVig_BOS, SurmountFan_IN and 36 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides
pat_auckland
Member
345
1,567
Jun 2024
Auckland, NZ
Sep 20, 2025 at 9:37 AM#19

As a healthcare provider, I want to add some clinical context to this discussion on GLP-1 and arterial inflammation March.

Building on what laura_annarbor said — the evidence base here is well-established. The key publications to reference are from the STEP program[1].

Key clinical points:

  1. Efficacy is dose-dependent and typically requires 4-5 weeks to reach steady state
  2. Side effect profile is predictable and usually manageable with standard protocols
  3. Monitoring should include baseline labs and follow-up at 3-month intervals
  4. Patient education significantly improves outcomes and adherence

Standard disclaimer: this is educational, not individualized medical advice.

References:
[1] See thread title for relevant study identification.
Last edited: Sep 20, 2025 at 1:37 PM
32 10MeganSA_TX, LarryQC_SD, wanda_boise and 29 others
Reply Quote Save Share Report
BethLabQueen
Senior Member
1,234
5,678
May 2024
Virginia
Online
Sep 20, 2025 at 9:54 AM#20

Subscribing to this thread. GLP-1 and arterial is exactly what I've been researching. 🙏

Last edited: Sep 20, 2025 at 10:54 AM
46 13wei_SG, cory_ATX, lori_vegas and 43 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register